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IgG4-related disease (IgG4-RD) is a recently described systemic ﬁbroinﬂammatory disease associated with elevated circulating
levels of IgG4 and manifests a wide spectrum of clinical presentations. Although serum IgG4 level has been described to be the
most sensitive and speciﬁc laboratory test for the diagnosis of IgG4-RD, it is recognized that an elevated serum IgG4 level can
be encountered in other diseases. In this study, we sought to identify the frequency of IgG4-RD and other disease associations in
patients with elevated serum IgG4 levels seen in clinical practice. Among 3,300 patients who underwent IgG subclass testing over
a 2-year period from January 2009 to December 2010, 158 (4.8%) had an elevated serum IgG4 level (>140mg/dL). IgG4 subclass
testing was performed for evaluation of suspected IgG4-RD or immunodeﬁciency. Twenty-nine patients (18.4%) had deﬁnite or
possible IgG4-RD. Among those patients without IgG4-RD, a broad spectrum of biliary tract, pancreatic, liver, and lung diseases,
as well as systemic vasculitis, was diagnosed. We conclude that patients with elevated serum IgG4 levels encountered in clinical
practice manifest a wide array of disorders, and only a small minority of them has IgG4-RD.
1.Introduction
IgG4-related disease (IgG4-RD) is a recently described sys-
temicﬁbroinﬂammatorydiseaseassociatedwithelevatedcir-
culating levels of IgG4 [1–4]. The pathologic lesion of IgG4-
RD is characterized by lymphoplasmacytic inﬂammation
with increased numbers of IgG4-positive plasma cells, ﬁbro-
sis, and phlebitis. Although initial descriptions of this dis-
order focused on its pancreatic presentation (autoimmune
pancreatitis), it has become apparent that IgG4-RD is a
systemic disease associated with a wide spectrum of clinical
manifestations involving virtually any organ in the body.
As initially observed in patients with autoimmune
pancreatitis, the majority of patients with IgG4-RD have
an elevated serum IgG4 level. Although serum IgG4 level
has been described to be the most sensitive and speciﬁc
laboratory test for the diagnosis of IgG4-RD, it is recognized
that an elevated serum IgG4 level can be encountered in
other diseases such as pancreatic cancer [5], atopic diseases
[6], and infections [7, 8]. Furthermore, serum IgG4 level
is elevated in up to 5% of the normal population [9, 10].
In this study, we sought to identify the spectrum of diseases
associated with elevated serum IgG4 levels in patients
encountered in clinical practice and the frequency of IgG4-
RD in this population.
2. Methods
Using a computer-assisted search, we identiﬁed all patients
who had serum IgG subclass levels determined on one or
more occasions at Mayo Rochester, MN, USA, during the 2-
year period from January 1, 2009 to December 31, 2010 and
selected those with an elevated serum IgG4 concentration
(>140mg/dL) for analysis [10]. The concentrations of IgG
subclass proteins in serum were measured in the Mayo Clinic
Clinical Laboratory by automated nephelometry in which
the concentrations of each protein were determined from
standard curves [11]. Human IgG4 latex reagent (Binding
Site Group Ltd, Birmingham, UK) was used in quantifying
the serum IgG4 concentration. Medical records of those
patients with elevated serum IgG4 levels were reviewed to
extract data regarding age, sex, clinical presentation, serum2 International Journal of Rheumatology
IgG4 level, indication for serum IgG subclass determina-
tion, imaging and biopsy results, and diagnoses. The main
diagnosis that resulted from evaluation of the presenting
clinical issue at the time of the serum IgG subclass testing
was identiﬁed.
For this study, the diagnostic criteria similar to those
proposed by Umehara and colleagues were employed [12].
The “deﬁnite” diagnosis of IgG4-RD required the following
criteria in addition to the known serum IgG4 elevation: (1)
clinical and/or radiologic evidence of lesions consistent with
IgG4-RD in one or more organs as previously described in
the literature and (2) IgG4 staining showing greater than 10
IgG4+ cells/high-power ﬁeld and IgG4+/IgG+ ratio greater
than 40% in the presence of lymphoplasmacytic inﬁltration
and ﬁbrosis. Patients who fulﬁll the organ-speciﬁc crite-
ria for IgG4-related autoimmune pancreatitis, IgG4-related
Mikulicz’s disease, and IgG4-related kidney disease were also
designatedashaving“deﬁnite”IgG4-RD[12].Thosepatients
clinically diagnosed based on clinical and imaging features
along with an elevated serum IgG4 level but not fulﬁlling
histopathologic criteria outlined above or in the absence
of tissue biopsy and exhibiting improvement with corticos-
teroid therapy were designated as “possible” IgG4-RD in
the absence of any other more likely diagnoses. None of our
patients met the criteria for “probable” IgG4-RD outlined by
Umehara and colleagues [12]. Non-IgG4-RD diagnoses were
determined based on the results of the diagnostic evaluation,
the clinicians’ diagnostic impression, and the subsequent
clinical course. Approval was obtained from the Mayo
Foundation Institutional Review Board prior to beginning
the study.
2.1. Statistical Analysis. Data are presented as mean ± SD
and percentages for categorical variables unless stated oth-
erwise. Demographic data were compared using the Fisher’s
exact test. Means of continuous variables were compared
between groups with a two-sample t-test. Serum IgG4 levels
between groups were compared using the Wilcoxon rank-
sum test. In all cases P-values <0.05 were considered sta-
tistically signiﬁcant.
3. Results
Weidentiﬁed3,300consecutivepatientswhohadtheirserum
IgG subclass testing performed on one or more occasions
during the 2-year interval from January 1, 2009 to December
31, 2010; 158 patients (4.8%) had at least one high serum
IgG4 level (>140mg/dL). The demographic features and
serumIgG4levelofthese158patientsareoutlinedinTable 1.
Indications for IgG subclass testing were evaluation for
possible IgG4-RD in 104 patients (65.8%) and to assess for
immunodeﬁciency (e.g., patients with recurrent or chronic
infections) in 54 patients (34.2%).
Twenty-ninepatients(18.4%)metthecriteriafordeﬁnite
or possible IgG4-RD (Table 2). The mean age of those with
IgG4-RD was older compared to those without IgG4-RD
(58.3 ± 16.9v e r s u s4 9 .9 ± 20.8, P<0.05) but the gender
distribution was not diﬀerent (P = 0.29). The serum
IgG4 level was signiﬁcantly higher in those with IgG4-RD
Table 1: Demographics and serum IgG4 levels (n = 158).
Characteristic All patients IgG4-RD
(n = 29)
No IgG4-RD
(n = 129)
Age, yr 51.4 ±20.35 8 .3 ±16.94 9 .9 ±20.8
Male sex,
no. (%) 98 (62) 21 (72) 77 (60)
Serum IgG4
level, mg/dL,
median (range)
202 (141–3150) 223 (149–3150) 187 (141–1030)
Data are presented as mean ± SD, unless otherwise indicated.
IgG4-RD: IgG4-related disease.
IgG4-RD includes deﬁnite and possible cases.
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Figure 1: Serum IgG4 levels for deﬁnite IgG4-RD, possible IgG4-
RD, and non-IgG4-RD subgroups. Median and interquartile range
(25% to 75%) are depicted.
compared to those with non-IgG4-RD diagnoses (P<0.001)
(Table 1). Furthermore, mean serum IgG4 level was higher
for those with deﬁnite IgG4-RD (940 ± 990) compared to
possible IgG4-RD (329 ± 318) which, in turn, was higher
comparedtonon-IgG4-RDsubgroup(226 ±127)(P<0.05)
(Figure 1). The mean serum IgG4/IgG ratio was signiﬁcantly
higher in patients with IgG4-RD (deﬁnite and possible)
compared to non-IgG4-RD patients (0.263 ± 0.239 versus
0.148 ± 0.061, P<0.01), but there was substantial overlap
in individual values between the two groups as shown in
Figure 2. Among 29 patients with IgG4-RD, 10 patients met
the criteria for deﬁnite IgG4-RD which included supportive
histopathologicﬁndingsontissuebiopsy.Of19patientswith
possible IgG4-RD, 12 had undergone biopsy procedures but
the biopsy ﬁndings did not meet the criteria for deﬁnite or
probable IgG4-RD diagnosis.
In the remaining 129 patients who did not have IgG4-
RD, the most common diagnoses were primary sclerosing
cholangitis, bronchiectasis, non-IgG4-related pancreatitis,
vasculitis, chronic rhinosinusitis, and pancreatic or bile duct
cancer. No speciﬁc diagnosis was achieved in 29 patients;International Journal of Rheumatology 3
Table 2: Spectrum of diagnoses associated with high serum IgG4
Levels (n = 158).
Diagnosis No. of patients (%)
IgG4-related disease 29 (18.4)
Deﬁnite 10
Probable 0
Possible 19
Respiratory diseases 32 (20.3)
Bronchiectasis 11
Chronic rhinosinusitis 7
Asthma 4
Idiopathic pulmonary ﬁbrosis 3
Sarcoidosis 2
Other respiratory diseases∗ 5
Biliary tract diseases 26 (16.5)
Primary sclerosing cholangitis 17
Cholangiocarcinoma 6
Biliary stricture or stone 3
Pancreatic diseases 19 (12.0)
Pancreatitis, not IgG4 related 10
Pancreatic cancer 6
Other pancreatic diseases† 3
Cirrhosis and other liver diseases 9 (5.7)
Vasculitis 9 (5.7)
Granulomatosis with polyangiitis
(Wegener’s) 5
The Churg-Strauss syndrome 3
Polyarteritis nodosa 1
Atopic dermatitis 1 (0.6)
Miscellaneous diseases‡ 4 (2.5)
No speciﬁc diagnosis 29 (18.4)
∗Other respiratory diseases (5 patients) included chronic pleuritis, emphy-
sema, ﬁbrosing mediastinitis, hypersensitivity pneumonitis, and recurrent
pneumonias, respectively.
†Other pancreatic diseases (3 patients) included intraductal papillary muci-
nous neoplasm, pancreatic cyst, and pancreatic insuﬃciency, respectively.
‡Miscellaneous diseases (4 patients) included lactose intolerance, neuroﬁ-
bromatosis, polymyositis, and psoriasis, respectively.
most common presenting complaints in these patients
included abdominal pain, fevers, and lymphadenopathy.
Pattern of organ involvement for these patients with
IgG4-RD is outlined in Table 3. Pancreas, bile ducts, and
orbital structures were most commonly involved. However,
these patients exhibited involvement in a number of other
organs including the salivary glands, retroperitoneal region,
lymph nodes, kidney, lung, pleura, sinuses, gastrointestinal
tract, and testis. Patients with two or more organ involve-
ments (n = 13) had a higher mean serum IgG4 level (840 ±
914) compared to those with single organ involvement (296
± 250) (P<0.01) (Figure 3).
All except one patient (surgical resection of a biliary
lesion) with IgG4-RD (deﬁnite or possible) were treated with
prednisone and improved. Twelve of 28 patients initially
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Figure 2: Serum IgG4/IgG ratios for IgG4-RD (deﬁnite and
possible IgG4-RD) and non-IgG4-RD subgroups. Median and
interquartile range (25% to 75%) are depicted.
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Figure 3: Serum IgG4 levels for patients with single-organ and
multiple-(two or more) organ involvement. Median and interquar-
tile range (25% to 75%) are depicted.
treated with prednisone experienced subsequent relapses
requiring reinstitution of prednisone alone or in combina-
tion with another immunosuppressive agent (including aza-
thioprine,methotrexate,andrituximab).Mediandurationof
followup was 23 months (range, 1 to 126 months).
4. Discussion
In this study we found a broad spectrum of diagnoses to
be associated with elevated serum IgG4 levels encountered
in the clinical practice setting; less than one-ﬁfth of these4 International Journal of Rheumatology
Table 3: Spectrum of organ involvement in patients with IgG4-RD
(n = 29).
Organ Deﬁnite cases,
n (n = 10)
Possible cases,
n (n = 19)
All cases,
n (%)
Pancreas 6 12 18 (62)
Bile ducts 2 9 11 (38)
Orbit 2 2 4 (14)
Retroperitoneum 1 2 3 (10)
Salivary glands 2 1 3 (10)
Lymph nodes 1 1 2 (7)
Lung 1 1 2 (7)
Gastrointestinal 1 1 2 (7)
Kidney 1 0 1 (3)
Pleura 1 0 1 (3)
Sinus 1 0 1 (3)
Mesentery 0 1 1 (3)
Testis 1 0 1 (3)
patients manifested evidence for IgG4-RD. IgG4 subclass
testing was ordered by clinicians for evaluation of possible
IgG4-RD or immunodeﬁciency, and thus it is not surprising
that various types of non-IgG4-related pancreatic and biliary
tract disorders were included along with chronic infections,
for example, bronchiectasis and sinusitis.
At the present time, there is no published international
consensus on the diagnostic criteria for IgG4-RD. Most
authors agree that deﬁnitive diagnosis of IgG4-RD requires
histologic conﬁrmation that includes the presence of char-
acteristic histopathologic features (lymphoplasmacytic inﬁl-
tration, ﬁbrosis, and obliterative phlebitis or arteritis) along
with immunostaining that demonstrates increased numbers
of IgG4+ cells. Various authors have used diﬀerent cutoﬀs
for IgG4 staining criteria. For the purposes of this study, we
used the diagnostic criteria recently published by Umehara
and colleagues [12] for “deﬁnite,” “probable,” and “possible”
IgG4-RD cases. In clinical practice, there are patients in
whom the diagnosis of IgG4-RD is likely and are empirically
treated without biopsy conﬁrmation. This may occur when
patients decline invasive procedures or the initial biopsy
specimen is nondiagnostic and additional biopsies are not
pursued for based on patient preference, perceived risks, or
lack of any other likely diagnosis.
All patients included in this analysis exhibited elevated
serum IgG4 levels and the degree of this elevation was not
used in determining the presence or absence of IgG4-RD.
Our patients with IgG4-RD exhibited a signiﬁcantly higher
serum IgG4 levels compared to those without IgG4-RD
although there was an overlap in their serum IgG4 values.
Some authors have suggested that a serum IgG4 concen-
tration that is more than twice the upper limit of normal
(>280mg/dL)ishighlyspeciﬁcforIgG-RD[13].Inthisstudy
13 of 29 patients (45%) with IgG4-RD and 18 of 129 patient
(14%) without IgG4-RD had a serum IgG4 concentration
that was >280mg/dL.
The sensitivity of elevated serum IgG4 levels in the
diagnosis of IgG4-RD has been reported to be in the range of
67% to 95% and speciﬁcity to be 90% to 97% [1, 2, 10, 13–
17]. Serum IgG4 elevation is present in 5% of the normal
population [9, 10] and has been observed in patients with
other disorders. For example, serum IgG4 levels have been
reported to be elevated in 7% to 10% of patients with
pancreatic cancer [5, 13]. Similarly, serum IgG4 elevation
has been seen in 5% to 9% of patients with other forms
of pancreatitis and benign pancreatic tumors [13]. Similar
spectrum of pancreatic diseases was also seen in our study
cohort.
Nonpancreatic disorders have also been associated with
elevated serum IgG4 levels. These include skin diseases
including atopic dermatitis [6] and pemphigus vulgaris [18,
19], as well as parasitic diseases [7, 8]. Our study cohort
included one patient with atopic dermatitis, but none had
pemphigus or parasitic diseases.
One-ﬁfth of our cohort had various respiratory dis-
eases. Van Nieuwkoop and colleagues [20]h a dp r e v i o u s l y
described an association between a polyclonal increase in
serum IgG4 subclass with acquired respiratory diseases.
Bronchiectasis and chronic rhinosinusitis were most respi-
ratory disorders in our study cohort likely reﬂecting the
fact that suspected immunodeﬁciency was one of the main
indications for IgG subclass testing in this population.
Primary sclerosing cholangitis (PSC) was the single most
common diagnosis in the non-IgG4-RD group. Nine of 17
patients with PSC had underlying inﬂammatory bowel dis-
ease. Elevated serum IgG4 levels have been described in 9%
to 12% of patients with PSC [21, 22]. Since diﬀerentiation of
autoimmune pancreatitis from pancreatic cancer and biliary
tract disease is a common clinical indication for IgG subclass
testing, it seems reasonable to expect that patients with
various types of biliary tract diseases including PSC and
cholangiocarcinoma will be encountered in those patients
with elevated serum IgG4 levels.
Vascular involvement has been seen in IgG4-RD mainly
in the form of aortitis, periaortitis, and inﬂammatory
abdominal aortic aneurysm [2, 23, 24]. Recently, elevated
serum IgG4 levels have been reported in patients with
Churg-Strausssyndrome[25,26]andhypocomplementemic
urticarial vasculitis [27]. Additionally, IgG4 antiproteinase
3 autoantibodies have been demonstrated to stimulate neu-
trophils to undergo a proinﬂammatory response suggesting
potential relevance in the pathogenesis of granulomatosis
with polyangiitis (Wegener’s) [28]. In this regard, it is inter-
esting to note that nine patients in our study cohort had sys-
temic vasculitis including granulomatosis with polyangiitis
and the Churg-Strauss syndrome. Prevalence of high serum
IgG4 level in patients with ANCA-associated vasculitis and
the relevance of IgG4 in the pathogenesis of these disorders
need to be explored further.
Although IgG4-related hepatopathy and hepatic inﬂam-
matory pseudotumors have been described [29–31], none of
our patients with liver disease and elevated serum IgG4 levels
fulﬁlled the criteria for IgG4-RD. They had other identiﬁable
causes including hepatitis C, drugs, sarcoidosis, and primary
biliary cirrhosis.International Journal of Rheumatology 5
As previously noted, serum IgG4 level is elevated in 5%
of the normal population [9, 10]. Similarly, 4.8% of 3,300
consecutive patients undergoing serum IgG subclass testing
at our institution over a 2-year period exhibited an elevated
serumIgG4level.Itseemsreasonabletoassumethatelevated
serum IgG4 level will be found coincidentally in a small
portion of various disease populations that are subjected to
IgG subclass testing, for example, patients with bronchiec-
tasis. None of our 54 patients with high serum IgG4 level
who had undergone IgG subclass testing for the indication
of suspected immunodeﬁciency had evidence of IgG4-RD.
It appears unlikely that there is a causal relationship between
the elevated serum IgG4 level and many of the diseases listed
in Table 2. It remains to be determined whether elevated
serumIgG4levelisarelevantﬁndinginotherdisordersother
than those recognized currently as IgG4-RD.
There are several limitations to this study. This study was
a retrospective survey with analysis limited to the clinical
data available in medical records and imaging studies. The
diagnostic evaluation for these patients was performed by
various clinicians at our institution according to their own
clinical judgment and patient context. It is possible that
some cases of IgG4-RD may have been missed particularly in
those patients without a speciﬁc diagnosis. In addition, the
extent of organ involvement may have been underestimated
in patients with IgG4-RD due to lack of relevant imaging
studies or biopsy specimens in the absence of standard
methodical evaluation.
We conclude that only a minority of patients with ele-
vated serum IgG4 levels encountered in clinical practice have
IgG4-RD. Furthermore, elevated serum IgG4 levels can be
seen in patients with many diﬀerent diseases, most of which
likely represent coincidental occurrence. Our ﬁndings rein-
force the principle that an elevated serum IgG4 level in
isolation is of limited diagnostic utility.
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